1. 1.Wallace, T. L. & Lopez-Berestein, G. (1998) Nystatin and liposomal nystatin. In Antimicrobial Therapy and Vaccines (Yu, V. L., Merigan, T. C., Barriere, S. & White, N. J., Eds), pp. 1185–91. Williams & Wilkins, Baltimore, MD.
2. 2.Gordon, L. E. (1995). Nystatin therapy in experimental coccichomycosis. American Review of Tuberculosis72, 67–70.
3. 3.Wallace, T. L., Paetznick, V., Cossum, P. A., López-Berestein, G., Rex, J. H. & Anaissie, E. (1997). Activity of liposomal nystatin against disseminated Aspergillus fumigatus in neutropenic mice. Antimicrobial Agents and Chemotherapy41, 2238–43.
4. 4.López-Berestein, G., Fainstein, V., Hopfer, R. L., Mehta, K., Sullivan, M. P., Keating, M. et al. (1985). Liposomal amphotericin-B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. Journal of Infectious Diseases151, 704–10.
5. 5.Gonzalez, C. E., Giri, N., Shetty, D., Klighys, K., Love, W., Sein, T. et al. (1996). Efficacy of a lipid formulation of nystatin against invasive pulmonary Aspergillosis. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA. Abstract B54. p. 31. American Society for Microbiology, Washington, DC.